GENOCEA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | -99.00% |
| 2023 | Genocea Biosciences, Inc. Went Out of Business | CI |
| 2023 | Liquidation Plan Approved for Genocea Biosciences, Inc. | CI |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to Genocea Fourth Qu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The Company has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.
| 1st Jan change | Capi. | |
|---|---|---|
| -99.00% | 58 | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- GNCAQ Stock
- News Genocea Biosciences, Inc.
- Transcript : Genocea Biosciences, Inc., Q4 2020 Earnings Call, Feb 11, 2021
